

Impression Sources 1,054 Patients for Incannex CBD-100 Oils

Impression Healthcare Limited ('Impression', 'IHL' or the 'Company') is pleased to announce that its wholly-owned medicinal cannabis company, Incannex Pharmaceuticals, has sourced 1,054 patients to supply CBD Oil under the Special Access Scheme ('SAS'), as administered by the TGA.

254 patient approvals for INCANNEXTM CBD-100 have been received in the past 30 days since being listed on the Cannvalate formulary, with a further 800 patients pending medical and TGA approval.

The acquisition of patients and subsequent sale of CBD-100 INCANNEXTM oil represent the Company's first revenues achieved from a medicinal cannabis product. Patients have been sourced via the Cannvalate network of prescribing doctors under Impression's broad strategic relationship with Cannvalate, which is the largest distributor of medicinal cannabis products in Australia.

Impression CEO and Managing Director; Mr Joel Latham said,

"Impression is pleased to have commenced selling INCANNEXTM CBD oils and achieved significant sales within a short period of time, with the assistance of Cannvalate.

We also have seen industry-wide competitive pricing pressures within the CBD oil market, which is exactly what our team predicted as the products are not unique or patentable without registration.

Impression's long-term competitive advantage and alpha profits will be generated via demonstration of clinical safety and efficacy, and registration of specific cannabinoid drugs for specific illnesses - that's why IHL is undertaking the drug discovery process, which is pre-clinical, phase 1, 2 and 3 clinical trials, on 3 of 4 of its unique drug candidates".

ENDS

About Impression Healthcare Limited (ASX: IHL)

Impression Healthcare Limited (IHL.ASX) is a first-in-class innovator and developer of a diversified mix of medicinal cannabis pharmaceutical products for global export potential. The Company is currently undertaking clinical programs to develop 4 uniquely formulated medicinal cannabis products for the treatment of Obstructive Sleep Apnoea (OSA), Traumatic Brain Injury/Concussion, Temporomandibular Joint Disorder and Periodontitis (Gum Disease).

Each indication represents major global markets with significant yearly sales. 3 of the 4 indications currently have no existing registered pharmacotherapy (drug) treatment, raising the possibility of patients receiving Government subsidies for products that demonstrate suitable safety and efficacy profiles in clinical trials.

There is an established body of research validating the hypothesis for the cannabinoids being used in Impression's chosen therapeutic areas and IHL has a strong patent filing strategy as it develops its products in conjunction with its medical advisory board of global key opinion leaders.

Further to its clinical programs, Impression also has its Australian licenses in place to import, export and distribute medicinal cannabis products and has launched a line of EU GMP approved CBD oil products under the brand, "INCANNEX". The INCANNEX cannabis-based oils are sold under Impression's product supply and distribution agreement with Cannvalate Pty Ltd, which is the largest network of cannabis medicine prescribers in Australia.

Yielding growing revenues to Impression is its customised oral devices manufacturing business. The oral devices division delivers high-quality products both direct to the consumer and via a growing B2B preferred practitioner network of dentists.

Investors: investors@impression.healthcare

Website: www.impression.healthcare